Cargando…

Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma

BACKGROUND: Lung adenocarcinoma (LADCA) patients with epidermal growth factor receptor (EGFR) mutations are in general associated with relatively high clinical response rate to EGFR-tyrosine kinase inhibitors (TKIs) but not all responded to TKI. It has therefore become important to identify the addi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, M, Miki, Y, Ebina, M, Abe, K, Mori, K, Narumi, S, Suzuki, T, Sato, I, Maemondo, M, Endo, C, Inoue, A, Kumamoto, H, Kondo, T, Yamada-Okabe, H, Nukiwa, T, Sasano, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493859/ https://www.ncbi.nlm.nih.gov/pubmed/23099808 http://dx.doi.org/10.1038/bjc.2012.422

Ejemplares similares

Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting
por: Tiernan, J P, et al.
Publicado: (2013)

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
por: Iida, K, et al.
Publicado: (2011)

Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status
por: Rego, R L, et al.
Publicado: (2010)

Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma
por: Sudo, T, et al.
Publicado: (2005)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Clinical significance of the reduced expression of G protein gamma 7 (GNG7) in oesophageal cancer
por: Ohta, M, et al.
Publicado: (2008)

Proteomic identification of secreted proteins as surrogate markers for signal transduction inhibitor activity
por: McClelland, C M, et al.
Publicado: (2007)

Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM
por: Bryan, R T, et al.
Publicado: (2015)

Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking
por: Sugio, K, et al.
Publicado: (2006)

Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer
por: Oshita, F, et al.
Publicado: (2006)

The Significance of MMP-1 in EGFR-TKI–Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting
por: Saito, Ryoko, et al.
Publicado: (2018)

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
por: Pichler, M, et al.
Publicado: (2012)

Mitotic centromere-associated kinesin is a novel marker for prognosis and lymph node metastasis in colorectal cancer
por: Ishikawa, K, et al.
Publicado: (2008)

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
por: Ålgars, A, et al.
Publicado: (2011)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib
por: Kimura, H, et al.
Publicado: (2006)

Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways
por: Nabeshima, A, et al.
Publicado: (2015)

Association of volume of self-directed versus assigned interpretive work with diagnostic performance of radiologists: an observational study
por: Amemiya, Shiori, et al.
Publicado: (2019)

Clinicopathological and biological significance of mitotic centromere-associated kinesin overexpression in human gastric cancer
por: Nakamura, Y, et al.
Publicado: (2007)

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
por: Modjtahedi, H, et al.
Publicado: (2012)

Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis
por: Ashraf, S Q, et al.
Publicado: (2009)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment
por: Mimori, K, et al.
Publicado: (2006)

Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients
por: Ruiz, M I Galleges, et al.
Publicado: (2009)

EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers
por: Fukuyoshi, Y, et al.
Publicado: (2008)

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
por: Takahashi, N, et al.
Publicado: (2014)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

Aberrant expression of RAB1A in human tongue cancer
por: Shimada, K, et al.
Publicado: (2005)

Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer
por: Ettl, T, et al.
Publicado: (2012)

Multimodal validation of focal enhancement in intracranial aneurysms as a surrogate marker for aneurysm instability
por: Larsen, Naomi, et al.
Publicado: (2020)

CD44s signals the acquisition of the mesenchymal phenotype required for anchorage-independent cell survival in hepatocellular carcinoma
por: Okabe, H, et al.
Publicado: (2014)

miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells
por: Higashi, T, et al.
Publicado: (2015)

Targeting EGFR and PI3K pathways in ovarian cancer
por: Glaysher, S, et al.
Publicado: (2013)

Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options
por: Scartozzi, M, et al.
Publicado: (2007)

Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis
por: Kouzu, Y, et al.
Publicado: (2006)

EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method
por: Watanabe, Kana, et al.
Publicado: (2016)

Assessment of Structural Glaucoma Progression
por: Miki, Atsuya
Publicado: (2012)

Can (18)F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysis
por: Du, Bulin, et al.
Publicado: (2021)

Bone marrow and peripheral blood expression of ID1 in human gastric carcinoma patients is a bona fide indicator of lymph node and peritoneal metastasis
por: Iwatsuki, M, et al.
Publicado: (2009)

Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma
por: Keller, J, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_91j25nhnm8gne1rn3h09jc5i4d